MAPT and Alzheimer disease: NAD+ levels are reduced in the animal models of AD, and cellular NAD+ levels are increased by supplementing NAD+ precursors to alleviate Aβ and tau lesions while preventing cognitive impairment (Brown et al., 2014; Scheibye-Knudsen et al., 2014).